Michael P. Frost

1 presentation

• W9. FIRST DOSE TREATMENT EFFECTS WITH INJECTABLE WEEKLY AND MONTHLY BUPRENORPHINE (CAM2038) AND THE RELATIONSHIP BETWEEN BUPRENORPHINE PLASMA CONCENTRATIONS AND WITHDRAWAL SUPPRESSION IN PARTICIPANTS WITH OPIOID USE DISORDER

  2026 ASCP Annual Meeting